Clinical and treatment characteristics of the patient population (N = 625) in relation to CNS relapse
| Characteristics . | With CNS relapse, N (%) . | Without CNS relapse, N (%) . | P . |
|---|---|---|---|
| Gender | .54 | ||
| Male | 15 (54) | 355 (59) | |
| Female | 13 (46) | 242 (41) | |
| Age | .043 | ||
| ≤60 y | 15 (54) | 208 (35) | |
| >60 y | 13 (46) | 389 (65) | |
| World Health Organization performance score | .69 | ||
| 0-1 | 20 (71) | 405 (68) | |
| 2-4 | 8 (29) | 192 (32) | |
| B-symptoms | .16 | ||
| Yes | 20 (71) | 355 (59) | |
| No | 7 (25) | 230 (39) | |
| Missing | 1 (4) | 12 (2) | |
| Bulky disease (> 10 cm) | .76 | ||
| Yes | 2 (7) | 65 (11) | |
| No | 25 (89) | 521 (87) | |
| Missing | 1 (4) | 11 (2) | |
| Ann Arbor Stage | .59* | ||
| I | 0 | 83 (14) | |
| II | 8 (29) | 111 (19) | |
| III | 5(18) | 138 (23) | |
| IV | 15 (54) | 249 (42) | |
| Missing | 16 (3) | ||
| Bone marrow involvement | .77 | ||
| Yes | 5 (18) | 120 (20) | |
| No | 23 (82) | 477 (80) | |
| Bone involvement | .11 | ||
| Yes | 3 (11) | 23 (4) | |
| No | 25 (89) | 574 | |
| Skin involvement | .009 | ||
| Yes | 6 (21) | 37 (6) | |
| No | 22 (79) | 560 (94) | |
| Pleural involvement | .19 | ||
| Yes | 3 (11) | 31 (5) | |
| No | 25 (89) | 566 (95) | |
| Kidney involvement | 1.0 | ||
| Yes | 0 | 4 (1) | |
| No | 28 (100) | 593 (99) | |
| Testicular involvement | .21 | ||
| Yes | 1 (4) | 4 (1) | |
| No | 27 (96) | 593 (99) | |
| Gastrointestinal involvement | .051 | ||
| Yes | 8 (29) | 84 (14) | |
| No | 20 (71) | 513 (86) | |
| Extranodal involvement | .009 | ||
| ≤1 | 19 (68) | 519 (87) | |
| >1 | 9 (32) | 78 (13) | |
| Lactate dehydrogenase | .16 | ||
| Normal | 7 (25) | 227 (38) | |
| Elevated | 20 (71) | 348 (61) | |
| Missing | 1 (4) | 22 (4) | |
| International Prognostic Index | |||
| 0-1 | 6 (22) | 143 (26) | .85 |
| 2-3 | 16 (59) | 312 (56) | .47 |
| 4-5 | 5 (19) | 102 (18) | .80 |
| Missing | 1 (4) | 40 (7) | |
| Histological diagnosis† | |||
| ALCL ALK pos | 3 (6) | 48 (94) | |
| ALCL ALK neg | 2 (2) | 98 (98) | |
| ALCL ALK unknown | 1 (3) | 31 (97) | |
| PTCL NOS | 15 (7) | 201 (93) | |
| AITL | 3 (3) | 90 (97) | |
| EATL | 4 (7) | 52 (93)‡ | |
| TCL UNS | 0 | 33 (6) | |
| ENKTL | 0 | 26 (4) | |
| SPTCL | 0 | 10 (2) | |
| HSTCL | 0 | 8 (1) | |
| Treatment | |||
| CHOP | 18 (64) | 302 (51) | |
| CHOEP | 10 (36) | 140 (23) | |
| Intensive treatment other than CHOP/CHOEP | — | 35 (6) | |
| Palliative chemotherapy | — | 47 (8) | |
| Radiotherapy only | — | 12 (2) | |
| No treatment or corticosteroids only | — | 61 (10) | |
| Intrathecal treatment | 3 (11) | 48 (8) | |
| Auto SCT | 5 (18) | 98 (17) | |
| Total number of patients | 28 | 597 |
| Characteristics . | With CNS relapse, N (%) . | Without CNS relapse, N (%) . | P . |
|---|---|---|---|
| Gender | .54 | ||
| Male | 15 (54) | 355 (59) | |
| Female | 13 (46) | 242 (41) | |
| Age | .043 | ||
| ≤60 y | 15 (54) | 208 (35) | |
| >60 y | 13 (46) | 389 (65) | |
| World Health Organization performance score | .69 | ||
| 0-1 | 20 (71) | 405 (68) | |
| 2-4 | 8 (29) | 192 (32) | |
| B-symptoms | .16 | ||
| Yes | 20 (71) | 355 (59) | |
| No | 7 (25) | 230 (39) | |
| Missing | 1 (4) | 12 (2) | |
| Bulky disease (> 10 cm) | .76 | ||
| Yes | 2 (7) | 65 (11) | |
| No | 25 (89) | 521 (87) | |
| Missing | 1 (4) | 11 (2) | |
| Ann Arbor Stage | .59* | ||
| I | 0 | 83 (14) | |
| II | 8 (29) | 111 (19) | |
| III | 5(18) | 138 (23) | |
| IV | 15 (54) | 249 (42) | |
| Missing | 16 (3) | ||
| Bone marrow involvement | .77 | ||
| Yes | 5 (18) | 120 (20) | |
| No | 23 (82) | 477 (80) | |
| Bone involvement | .11 | ||
| Yes | 3 (11) | 23 (4) | |
| No | 25 (89) | 574 | |
| Skin involvement | .009 | ||
| Yes | 6 (21) | 37 (6) | |
| No | 22 (79) | 560 (94) | |
| Pleural involvement | .19 | ||
| Yes | 3 (11) | 31 (5) | |
| No | 25 (89) | 566 (95) | |
| Kidney involvement | 1.0 | ||
| Yes | 0 | 4 (1) | |
| No | 28 (100) | 593 (99) | |
| Testicular involvement | .21 | ||
| Yes | 1 (4) | 4 (1) | |
| No | 27 (96) | 593 (99) | |
| Gastrointestinal involvement | .051 | ||
| Yes | 8 (29) | 84 (14) | |
| No | 20 (71) | 513 (86) | |
| Extranodal involvement | .009 | ||
| ≤1 | 19 (68) | 519 (87) | |
| >1 | 9 (32) | 78 (13) | |
| Lactate dehydrogenase | .16 | ||
| Normal | 7 (25) | 227 (38) | |
| Elevated | 20 (71) | 348 (61) | |
| Missing | 1 (4) | 22 (4) | |
| International Prognostic Index | |||
| 0-1 | 6 (22) | 143 (26) | .85 |
| 2-3 | 16 (59) | 312 (56) | .47 |
| 4-5 | 5 (19) | 102 (18) | .80 |
| Missing | 1 (4) | 40 (7) | |
| Histological diagnosis† | |||
| ALCL ALK pos | 3 (6) | 48 (94) | |
| ALCL ALK neg | 2 (2) | 98 (98) | |
| ALCL ALK unknown | 1 (3) | 31 (97) | |
| PTCL NOS | 15 (7) | 201 (93) | |
| AITL | 3 (3) | 90 (97) | |
| EATL | 4 (7) | 52 (93)‡ | |
| TCL UNS | 0 | 33 (6) | |
| ENKTL | 0 | 26 (4) | |
| SPTCL | 0 | 10 (2) | |
| HSTCL | 0 | 8 (1) | |
| Treatment | |||
| CHOP | 18 (64) | 302 (51) | |
| CHOEP | 10 (36) | 140 (23) | |
| Intensive treatment other than CHOP/CHOEP | — | 35 (6) | |
| Palliative chemotherapy | — | 47 (8) | |
| Radiotherapy only | — | 12 (2) | |
| No treatment or corticosteroids only | — | 61 (10) | |
| Intrathecal treatment | 3 (11) | 48 (8) | |
| Auto SCT | 5 (18) | 98 (17) | |
| Total number of patients | 28 | 597 |
ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALK u, anaplastic lymphoma kinase status unknown; Auto SCT, autologous stem cell transplantation; EATL, enteropathy-associated T-cell lymphoma; ENKTL, extranodal NK/T-cell lymphoma, nasal type; HSTCL, hepatosplenic T-cell lymphoma; PTCL NOS, peripheral T-cell lymphoma not otherwise specified; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; TCL U, T-cell lymphoma unspecified.
Stage I-II compared with stage III-IV.
Frequencies given for each histological group.
Including 2 patients with EATL type II.